New Liver Transplants Study Findings Have Been Reported from Center for Drug Evaluation and Research (Approval of Mycophenolate Mofetil for Prophylaxis of Organ Rejection in Pediatric Recipients of Heart or Liver Transplants: A Regulatory...).

A recent study conducted by the Center for Drug Evaluation and Research has reported new findings on liver transplants. The study focused on the use of mycophenolate mofetil (MMF) as a prophylaxis for organ rejection in pediatric recipients of heart or liver transplants. The study found that MMF, when used in combination with other immunosuppressants, was effective in preventing organ rejection in pediatric patients. The recommended dosage for MMF in pediatric liver and heart transplant patients is a starting dose of 600 mg/m2, with a maximum of 900 mg/m2 twice daily. The study emphasizes the importance of individualized dosing based on clinical assessment. [Extracted from the article]